India’s Strategy for the Future of Biopharma

India’s Union Budget 2026–27 introduced a defining initiative for the life sciences sector: Biopharma SHAKTI. More than a funding announcement, Biopharma SHAKTI represents a long-term structural strategy — one aimed at strengthening India’s…

Continue Reading

Atmanirbhar Bharat in Biopharma

Republic Day is a time for reflection, not just on national identity, but on what self-reliance truly means for India’s life sciences industry. In the early stages of India’s biotech journey,…

Continue Reading

Why was deNOVO Biolabs found?

In 2013, a small group of technocrats with deep experience in biotechnology and a shared frustration with a systemic gap in reagent quality came together with a mission: to change…

Continue Reading

Why HCP & HCD need different strategies?

In the development and manufacture of biologics like monoclonal antibodies, recombinant proteins and vaccines—process-related impurities such as host cell DNA (HCD) and host cell proteins (HCPs) are unavoidable byproducts of the expression system used to…

Continue Reading

End of content

No more pages to load

Close Navigation